0819 Momenta JNJ
BioCentury & Getty Images


Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

Myasthenia gravis POC readout closely preceded pharma’s premium bid

A proof-of-concept readout in generalized myasthenia gravis closely preceded the pharma’s premium bid.

Aug 19, 2020 | 9:52 PM GMT

Momenta’s 2018 decision to reorganize its business around its innovative pipeline was the critical step that positioned the biotech for its $6.5 billion takeout by J&J, announced Wednesday.

The company had deprioritized its complex generics and biosimilars businesses nearly two years

Read the full 833 word article

How to gain access

Continue reading with a
two-week free trial.